Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Phase-Appropriate CMC for Base Editor Therapeutics

PROVEN INTELLIGENCE IN GENE EDITING CMC.

Phase-Appropriate CMC for Base Editor Therapeutics

Phase-Appropriate CMC for Base Editor Therapeutics: Swissmedic Regulatory Alignment

CELL & GENE | RNA | BIOLOGICS

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Executive Summary: Base editor therapeutics present distinct Chemistry, Manufacturing, and Controls (CMC) challenges that require a forward-looking, phase-appropriate strategy. A successful Investigational Medicinal Product Dossier (IMPD) submission to Swissmedic or other European authorities depends on robust analytical characterization of both the guide RNA and the editor protein components, as well as the delivery system. The strategy must evolve from establishing initial safety and feasibility in early phases to demonstrating process consistency and scalability for later clinical stages.

Frequently Asked Questions

What are Swissmedic’s primary CMC concerns for base editor therapeutics submitted as Advanced Therapy Medicinal Products (ATMPs)?

Swissmedic, in alignment with EMA guidelines for ATMPs, focuses intensely on the characterization, purity, and potency of the final product. For base editors, this includes demonstrating the integrity and sequence fidelity of the guide RNA, the purity of the editor protein, and rigorous quantification of potential off-target editing events. A comprehensive analytical package is expected.

How does a phase-appropriate CMC strategy for gene editing systems differ from traditional viral vector programs?

While both require stringent controls, gene editing CMC places a greater emphasis on the multi-component nature of the product. The analytics must separately characterize the guide RNA, the nuclease or editor protein, and the delivery vehicle (e.g., LNP or AAV). The potential for off-target activity also necessitates specialized analytical assays not typically required for standard AAV gene replacement therapies.

What analytical assays are required to characterize the guide RNA and base editor components for an IMPD submission?

A foundational analytical package for an IMPD submission includes methods to confirm gRNA identity and sequence (e.g., sequencing, mass spectrometry), assess its purity and integrity (e.g., HPLC, capillary electrophoresis), and characterize the editor protein. A well-defined cell-based potency assay is also required to demonstrate the intended biological activity.

A tailored, data-driven preclinical strategy is the foundation for any successful advanced therapy program. For base editor therapeutics, this requires a CMC framework that anticipates regulatory expectations and addresses the unique biology of the platform. The manufacturing and analytical controls must account for a multi-component system: the guide RNA (gRNA), the base editor protein (often a Cas nuclease variant fused to a deaminase), and the delivery system.

Defining the Analytical Strategy for a Multi-Component Product

The initial focus of a CMC program is the rigorous characterization of each starting material. This involves developing and qualifying analytical methods to ensure the identity, purity, and stability of both the gRNA and the editor protein. Any impurities or degradants must be identified and controlled to mitigate potential risks to product efficacy or patient safety.

The delivery vehicle, whether a lipid nanoparticle (LNP) or a viral vector like AAV, introduces its own set of CMC requirements. Historical work with viral vectors has shown that insufficient vector optimization can limit expression to sub-therapeutic levels, compromising clinical outcomes (PMID: 21609134). Likewise, the immunogenicity of a delivery system’s components, such as an AAV capsid, remains a significant variable that must be analytically profiled and understood to de-risk the program (PMID: 28323492).

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A Phase-Appropriate Approach to CMC and Regulatory Submissions

A CMC strategy must be dynamic, evolving with the program as it advances toward the clinic. The requirements for a first-in-human study differ significantly from those for a pivotal Phase 3 trial.

  • Early-Phase Focus (Pre-IND/IMPD): The primary goal is to establish a process that can reliably produce material for IND-enabling toxicology studies. The analytical package must be sufficient to ensure product safety and establish a preliminary link between the product’s characteristics and its biological activity.

  • Late-Phase Focus (Pivotal Trials): The emphasis shifts to demonstrating process consistency, robustness, and scalability. Assays must be fully validated, and the manufacturing process must be locked down to ensure that the material used in pivotal trials is representative of the future commercial product.

Franklin Biolabs provides the scientific and operational framework to navigate these complex requirements. Our approach, which has contributed to a 100% successful IND rate for programs since 2019, is based on the deep institutional knowledge of our founding scientific leadership and principal scientists. While Franklin Biolabs formally launched in 2024, our team’s track record provides the proven intelligence to accelerate timelines, often reaching IND within 18-24 months. This work is conducted within our expansive facilities, which span over 100,000 square feet of laboratory and in vivo study space.

By integrating CMC development with preclinical planning, we help sponsors build a comprehensive data package designed for successful submissions to global regulatory bodies, including Swissmedic and the EMA. This alignment is a core component of our work within our Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities